This real-world clinical study assessed the effectiveness of tirzepatide, a dual GIP/GLP-1 receptor agonist, in combination with structured lifestyle modification among adults with type 2 diabetes and overweight or obesity. Conducted through a virtually assisted diabetes care platform, the 8-week intervention enrolled 41 participants who received tirzepatide starting at 2.5 mg, with some escalating to 5 mg based on response. Of the participants, 31 continued treatment and completed an 8-week follow-up, exhibiting significant weight reduction (4.56 ? 2.97; p <0.001). Subgroup analysis revealed significantly greater weight loss in the 5 mg dose-escalation group compared to the 2.5 mg group (5.22 ? 3.63 kg vs. 3.84 ? 1.94 kg; p<0.001). Significant reductions were also observed in BMI, waist circumference, and blood glucose levels, with dose-dependent trends evident. Adverse events were predominantly mild and transient, primarily gastrointestinal in nature. The combined pharmacologic and lifestyle approach demonstrated promising efficacy and safety in short-term diabetes management, highlighting tirzepatide?s potential role in real-world integrated care models.
Mehra et al. (Fri,) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: